216 related articles for article (PubMed ID: 21418500)
1. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
3. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
Offermanns S
Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment target for Parkinson's disease.
Wakade C; Chong R
J Neurol Sci; 2014 Dec; 347(1-2):34-8. PubMed ID: 25455298
[TBL] [Abstract][Full Text] [Related]
5. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
6. Niacin stimulates adiponectin secretion through the GPR109A receptor.
Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.
Kim HY; Jadhav VB; Jeong DY; Park WK; Song JH; Lee S; Cho H
Arch Pharm Res; 2015 Jun; 38(6):1019-32. PubMed ID: 25599616
[TBL] [Abstract][Full Text] [Related]
8. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic acid: recent developments.
Kamanna VS; Vo A; Kashyap ML
Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
[TBL] [Abstract][Full Text] [Related]
10. Novel patent publications on high-affinity nicotinic acid receptor agonists.
Shen HC; Colletti SL
Expert Opin Ther Pat; 2009 Jul; 19(7):957-67. PubMed ID: 19552512
[TBL] [Abstract][Full Text] [Related]
11. Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
Jung JK; Johnson BR; Duong T; Decaire M; Uy J; Gharbaoui T; Boatman PD; Sage CR; Chen R; Richman JG; Connolly DT; Semple G
J Med Chem; 2007 Apr; 50(7):1445-8. PubMed ID: 17358052
[TBL] [Abstract][Full Text] [Related]
12. Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.
Carballo-Jane E; Gerckens LS; Luell S; Parlapiano AS; Wolff M; Colletti SL; Tata JR; Taggart AK; Waters MG; Richman JG; McCann ME; Forrest MJ
J Pharmacol Toxicol Methods; 2007; 56(3):308-16. PubMed ID: 17643322
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acid receptor subtypes and their ligands.
Soudijn W; van Wijngaarden I; Ijzerman AP
Med Res Rev; 2007 May; 27(3):417-33. PubMed ID: 17238156
[TBL] [Abstract][Full Text] [Related]
14. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
Shen HC; Ding FX; Deng Q; Wilsie LC; Krsmanovic ML; Taggart AK; Carballo-Jane E; Ren N; Cai TQ; Wu TJ; Wu KK; Cheng K; Chen Q; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
J Med Chem; 2009 Apr; 52(8):2587-602. PubMed ID: 19309152
[TBL] [Abstract][Full Text] [Related]
16. Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A.
Shen HC; Szymonifka MJ; Kharbanda D; Deng Q; Carballo-Jane E; Wu KK; Wu TJ; Cheng K; Ren N; Cai TQ; Taggart AK; Wang J; Tong X; Waters MG; Hammond ML; Tata JR; Colletti SL
Bioorg Med Chem Lett; 2007 Dec; 17(24):6723-8. PubMed ID: 18029181
[TBL] [Abstract][Full Text] [Related]
17. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
18. Novel Niacin Receptor Agonists: A Promising Strategy for the Treatment of Dyslipidemia.
Kothawade PB; Thomas AB; Chitlange SS
Mini Rev Med Chem; 2021; 21(17):2481-2496. PubMed ID: 33550969
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.
Shen HC; Taggart AK; Wilsie LC; Waters MG; Hammond ML; Tata JR; Colletti SL
Bioorg Med Chem Lett; 2008 Sep; 18(18):4948-51. PubMed ID: 18752940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
